Does adjuvant vaccine therapy really have activity in malignant melanoma?
Wheatley
Keith
K
Ives
Natalie J
NJ
Lorigan
Paul
P
D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D006801:Humans; D016233:Immunotherapy, Active; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008545:Melanoma / Q000556:secondary / Q000628:therapy*; D009364:Neoplasm Recurrence, Local; D011994:Recombinant Proteins; D012107:Research Design; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*
D019496:Cancer Vaccines; D004338:Drug Combinations; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins